[company_age]7.0[/company_age][employees]51-200 employees[/employees][funding]Series B[/funding][description]Amphista Therapeutics is a next-generation targeted protein degradation (TPD) company that is rapidly advancing a portfolio of innovative therapeutic candidates from early-stage discovery to clinical-stage research and commercialization. The company's proprietary Eclipsys™ Drug Development platform enables the development of novel protein-degrading therapeutics with superior levels of efficacy and broad therapeutic applicability. Amphista's global operations and progress are guided by its mission to unlock the full therapeutic potential of TPD and make a positive difference for patients.\n\nAmphista is distinguished from its competitors by its focus on developing next-generation TPD therapies that address the limitations of traditional TPD approaches. The company's Eclipsys™ platform expands the therapeutic applications of TPD by utilizing a broader range of protein-degrading mechanisms. This approach has the potential to treat diseases with high unmet medical needs.\n\nAmphista is led by a team of experts in biomedical research and drug development, with support from leading life science investors. The company is built on the groundbreaking science of Professor Alessio Ciulli, a world leader in the field of targeted protein degradation.\n\nAmphista's unique approach to TPD, combined with its experienced team and strong financial backing, positions the company as a leader in the development of next-generation protein-degrading therapeutics.[/description][ps]Novel protein-degrading therapeutics[/ps]